Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyUpper Ohio Experimental Coverage | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedHealth Plan of the Upper Ohio Valley, Inc.Policy 21412333

    Experimental/Investigational Services and Emerging Technologies

    Customize your policy alerts

    Sign up for healthplanofupperohiovalley Policy 21412333 alerts

    Get alerted when Policy 21412333 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines when treatments, procedures, equipment, drugs, supplies, interventions, and emerging technologies are considered experimental or investigational. These services are non-covered, subject to applicable Medicare, Medicaid, clinical-trial, and line-of-business coverage rules.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyExperimental/Investigational Services and Emerging Technologies
    Policy CodePolicy 21412333
    Change TypeModified
    Effective DateNov 1, 2026
    Next Review DateNov 1, 2026
    Key ActionObtain precertification for CPT 55880, transrectal high-intensity-focused ultrasound ablation of benign prostate tissue.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history records repeated additions of new CPT, HCPCS, Category III, PLA, and other billing codes for services considered experimental, investigational, or emerging.

    The policy history records removal of deleted, inactive, or separately addressed codes and codes affected by changes in coverage for particular lines of business.

    The policy history records revisions to code descriptions, Medicare and Medicaid notes, clinical-trial coverage-with-evidence-development information, references, and examples of technologies such as the AngelMed Guardian and Volara systems.

    The policy states that medical records must document the applicable medical-necessity criteria and may be audited by the plan after payment.

    61Document pages
    7Determination criteria
    Non-coveredDefault benefit status
    55880HIFU precertification code
    6NOPAIN Act exceptions

    Experimental and Investigational Coverage Criteria

    Experimental/investigational determination

    A service is considered experimental or investigational when ANY of the following criteria are met:

    Experimental/investigational criteria: The service does not have FDA approval for the specific relevant indication; or current scientific evidence does not permit conclusions about its effects on health outcomes; or the service has not been proven to be as safe or effective as, or better than, alternative services; or the service has not been proven to improve health outcomes; or the service has not been proven applicable outside the research setting; or adequate research is unavailable because the service has not been adequately studied; or the service falls under a Medicare statutory exclusion.

    Any one criterion is sufficient for experimental/investigational classification.

    Cardiac contractility modulation

    Cardiac contractility modulation therapy is experimental, investigational, or unproven for all indications.

    Cardiac contractility modulation: The service involves cardiac contractility modulation therapy administered by the Impulse Dynamics Optimizer system or OPTIMIZER Integra CCM-D System; and the effectiveness of this approach has not been established.
    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyExperimental/Investigational Services and Emerging Technologies
    Policy CodePolicy 21412333
    Change TypeModified
    Effective DateNov 1, 2026
    Next Review DateNov 1, 2026
    Key ActionObtain precertification for CPT 55880, transrectal high-intensity-focused ultrasound ablation of benign prostate tissue.
    SourceLink
    On This Page
    Experimental and Investigational Coverage CriteriaCode Lists, Exceptions, and Historical CodingProvider Documentation and Billing ActionsPolicy BackgroundKey Definitions

    Clinical trials are underway, although some have been terminated because of slow enrollment. Removal procedures may be covered for fully funded plans when performed for unrelated issues such as pain or infection.

    Interatrial septal shunt device for heart failure

    The following service is experimental, investigational, and unproven for treatment of heart failure:

    Experimental or unproven status: Percutaneous transcatheter implantation of an interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist when performed.

    The service is identified as experimental, investigational, and unproven for the treatment of heart failure.

    Experimental and emerging services

    Services and technologies listed in this section are treated as experimental, investigational, emerging, or otherwise subject to specific noncoverage or authorization rules.

    Service-specific policy application: Coverage is determined under the applicable service-specific policy provisions. Inclusion in a code list does not by itself establish coverage.

    The listed Category I codes are not all-inclusive; omission of a procedure or technology does not necessarily imply that it is covered.

    Barostim Neo System

    The Barostim Neo System is not covered.

    Barostim noncoverage: The initial open implantation of the Barostim Neo System and related revisions, replacements, supplies, accessories, and supplemental listed codes are not covered.

    Supplemental non-covered codes include 64655, 64656, 64657, 64658, and 64659. Non-related services, such as treatment for pain or infection, may be covered for fully funded plans when otherwise eligible.

    Services classified as experimental or investigational are deemed non-covered. This applies when the treatment, procedure, facility, equipment, drug, service, supply, or intervention has not been determined to be medically effective for the condition being treated.

    Unless another policy specifically addresses the service, Category III and “T” codes are considered potentially experimental, investigational, and/or unproven. These temporary codes track emerging technologies, services, and procedures and may not meet all clinical-efficacy documentation requirements for Category I codes.

    CPT 0640T for noncontact near-infrared spectroscopy is not medically reasonable or necessary under Medicare and section 1862(a)(1)(A), except when used for screening for peripheral arterial disease.

    The Barostim Neo System is not covered. Noncoverage also applies to its revisions, replacements, supplies, accessories, and supplemental codes 64655–64659.

    The Category I code list is not all-inclusive. Omitting a procedure, service, or technology from the list does not necessarily mean that it is covered.

    Disposable elastomeric infusion pumps are not covered in the home when billed as disposable items with the applicable supply codes. The AmbIT pump may be covered for qualifying Medicare members when used for post-surgical pain management in eligible hospital outpatient departments or ambulatory surgical centers under the NOPAIN Act.

    For the Volara oscillation and lung expansion therapy system, supplies are billed with HCPCS A7021. In a facility setting, the OLE therapy device should not be reported with the listed HCPCS supply codes.

    Most plans exclude Myomo MyoPro myoelectric limb orthoses because the FDA considers them exercise equipment.

    The inclusion or omission of a Category III or “T” code does not establish that the code or service is medically necessary or covered. Coverage remains subject to applicable policy provisions and benefit requirements.

    Under Medicare, CPT 0640T is not medically reasonable or necessary under section 1862(a)(1)(A), except for the separately identified peripheral arterial disease screening use.

    Code Lists, Exceptions, and Historical Coding

    Experimental, investigational, and potentially unproven Category III/T codesmixedExperimental
    0174TComputer-aided detection with physician review for chest radiograph lesion detection, concurrent with primary interpretation
    0175TComputer-aided detection with physician review for chest radiograph lesion detection, remote from primary interpretation
    0198TMeasurement of ocular blood flow by repetitive intraocular pressure sampling
    0200TPercutaneous sacral augmentation, unilateral
    0201TPercutaneous sacral augmentation, bilateral
    0202TPosterior vertebral joint arthroplasty
    0207TAutomated evacuation of meibomian glands using heat and intermittent pressure, unilateral
    0219TPlacement of a posterior intra-facet implant, unilateral or bilateral
    0220TPlacement of a posterior intra-facet implant, unilateral or bilateral
    0221TPlacement of a posterior intra-facet implant, unilateral or bilateral
    1–10 of 91
    1/10
    Experimental, investigational, or emerging CPT Category III servicesCPTExperimental
    0563TEvacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral.
    0565TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation.
    0566TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral.
    0569TUnilateral transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis, TriClip Transcatheter Tricuspid Valve Repair System (Abbott).
    0570TTranscatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session; TriClip Transcatheter Tricuspid Valve Repair System (Abbott).
    0581TAblation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral.
    Experimental, investigational, or emerging CPT Category III servicesCPTExperimental
    0582TTransurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.
    0583TTympanostomy requiring insertion of ventilating tube, using an automated tube delivery system.
    0598TNon-contact real-time fluorescence wound imaging for bacterial presence, location, and load, per session; first anatomic site.
    0599TNon-contact real-time fluorescence wound imaging for bacterial presence, location, and load, per session; each additional anatomic site.
    0600TAblation, irreversible electroporation; one or more tumors per organ, including imaging guidance, when performed, percutaneous.
    0601TAblation, irreversible electroporation; one or more tumors, including fluoroscopic guidance when performed, percutaneous.
    0602TAblation, irreversible electroporation; one or more tumors, including ultrasound guidance when performed, open.
    0603TGlomerular filtration rate measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent.
    0610TMagnetic resonance spectroscopy for determination and localization of discogenic pain; transmission of biomarker data for software analysis.
    0612TMagnetic resonance spectroscopy for determination and localization of discogenic pain; interpretation and report.
    1–10 of 14
    1/2
    Experimental, investigational, or emerging CPT Category III servicesCPTExperimental
    0621TTrabeculostomy ab interno by laser.
    0622TTrabeculostomy ab interno by laser; with use of ophthalmic endoscope.
    0633TCT breast including 3D rendering, unilateral; without contrast material.
    0634TCT breast including 3D rendering, unilateral; with contrast material(s).
    0635TCT breast including 3D rendering, unilateral; without contrast followed by contrast material(s).
    0636TCT breast including 3D rendering, bilateral; without contrast material(s).
    0637TCT breast including 3D rendering, bilateral; with contrast material(s).
    0638TCT breast including 3D rendering, bilateral; without contrast followed by contrast material(s).
    0639TWireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance when performed.
    0640TNoncontact near-infrared spectroscopy for measurement of deoxyhemoglobin, oxyhemoglobin, and tissue-oxygenation ratio, other than screening for peripheral arterial disease; image acquisition, interpretation, and report; first anatomic site.
    1–10 of 13
    1/2
    Experimental, investigational, or emerging CPT Category III servicesCPTExperimental
    0649TQuantitative magnetic resonance for analysis of tissue composition, including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy.
    0655TTransperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging.
    0656TAnterior lumbar or thoracolumbar vertebral body tethering, anterior; up to 7 vertebral segments.
    0657TAnterior lumbar or thoracolumbar vertebral body tethering, anterior; 8 or more vertebral segments.
    0668TBackbench standard preparation of cadaver or living donor uterine allograft prior to transplantation.
    0669TBackbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each.
    0670TBackbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each.
    0672TEndovaginal cryogen-cooled, monopolar radiofrequency remodeling of tissues surrounding the female bladder neck and proximal urethra for urinary incontinence; the VIVEVE I and ThermiVa procedures.
    0693TAutomated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report.
    0701TMolecular fluorescent imaging of suspicious nevus; each additional lesion; Orlucent Handheld Fluorescent Molecular Imaging System.
    1–10 of 14
    1/2
    Experimental, investigational, or emerging CPT Category III servicesCPTExperimental
    0710TNoninvasive arterial plaque analysis using software processing of data from non-coronary CT angiography, including data preparation and transmission, quantification of vessel-wall structure and composition, and assessment for lipid-rich necrotic core plaque.
    0711TNoninvasive arterial plaque analysis using software processing of data from non-coronary CT angiography; data preparation and transmission.
    0712TNoninvasive arterial plaque analysis using software processing of data from non-coronary CT angiography; quantification of vessel-wall structure and composition and assessment for lipid-rich necrotic core plaque.
    0713TNoninvasive arterial plaque analysis using software processing of data from non-coronary CT angiography; data review, interpretation, and report.
    0716TCardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score.
    0719TPosterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment.
    0727TVestibular device implantation, unilateral.
    0728TRemoval and replacement of implanted vestibular device, unilateral.
    0729TDiagnostic analysis of vestibular implant, unilateral; with initial programming.
    0730TDiagnostic analysis of vestibular implant, unilateral; with subsequent programming.
    1–10 of 25
    1/3
    Experimental, investigational, or emerging CPT Category III servicesCPTExperimental
    0770TVirtual reality technology to assist therapy.
    0771TVirtual reality procedural dissociation services provided by the same physician or qualified health care professional performing the supported service; initial 15 minutes.
    0772TVirtual reality procedural dissociation services; each additional 15 minutes.
    0773TVirtual reality procedural dissociation services provided by a different physician or qualified health care professional; initial 15 minutes.
    0774TVirtual reality procedural dissociation services provided by a different physician or qualified health care professional; each additional 15 minutes.
    0776TTherapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device and monitoring, 30 minutes of treatment.
    0777TReal-time pressure-sensing epidural guidance system.
    0778TSurface mechanomyography with concurrent application of inertial measurement unit sensors for measurement of range of motion, posture, gait, and muscle function.
    0779TGastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report.
    0781TBronchoscopy with insertion of esophageal protection device and circumferential radiofrequency destruction of pulmonary nerves; bilateral mainstem bronchi.
    1–10 of 31
    1/4
    Emerging technology codesCPTExperimental
    0820TSubfascial tibial nerve stimulation; BlueWind Revi
    Emerging technology and device codesCPTExperimental
    0640TCompanion code referenced for noncontact near-infrared spectroscopy
    0859TCompanion code referenced for noncontact near-infrared spectroscopy for peripheral arterial disease
    0860TCompanion code referenced for noncontact near-infrared spectroscopy
    0864TLow-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy
    0868THigh-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report
    0869TInjection(s), bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance when performed
    0870TImplantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, tunneled indwelling bladder and peritoneal catheters, pump connections, imaging, and initial programming when performed
    0871TReplacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, initial programming, and imaging when performed
    0872TReplacement of indwelling bladder and peritoneal catheters, including tunneling and connection with a previously implanted peritoneal ascites pump, imaging, and programming when performed
    0873TRevision of a subcutaneously implanted peritoneal ascites pump system, any component
    1–10 of 11
    1/2
    Algorithmic analysis and ablation codesCPTExperimental
    0888THistotripsy of malignant renal tissue, including imaging guidance
    0898TNoninvasive prostate cancer estimation map derived from augmentative analysis of image-guided fusion biopsy and pathology, including margin visualization, determination, and physician interpretation and report
    0899TNoninvasive determination of absolute quantitation of myocardial blood flow derived from augmentative algorithmic analysis of contrast cardiac magnetic resonance with pharmacologic stress, including interpretation and report
    0900TAssistive algorithmic analysis of a contrast cardiac magnetic resonance dataset with pharmacologic stress, including interpretation and report
    Device implantation, monitoring, and HIFU codesCPTExperimental
    0906TConcurrent optical and magnetic stimulation therapy, wound assessment and dressing care; first application, total wound surface area <=50 sq cm
    0907TConcurrent optical and magnetic stimulation therapy, wound assessment and dressing care; each additional application, total wound surface area <=50 sq cm
    0915TInsertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance and evaluation/programming; pulse generator and dual transvenous electrodes/leads
    0916TInsertion of permanent cardiac contractility modulation-defibrillation system component(s); pulse generator only
    0917TInsertion of permanent cardiac contractility modulation-defibrillation system component(s); single transvenous lead only
    0921TRemoval of a permanent cardiac contractility modulation-defibrillation system component; single transvenous defibrillation lead only
    0922TRemoval of a permanent cardiac contractility modulation-defibrillation system component; dual transvenous pacing and defibrillation leads only
    0923TRemoval and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only
    0924TRepositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming
    0925TRelocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator
    1–10 of 13
    1/2
    Emerging diagnostic, therapeutic, and monitoring codesCPTExperimental
    0957TRevision of sub-scalp implanted electrode array, receiver, and telemetry unit
    0958TRemoval of sub-scalp implanted electrode array, receiver, and telemetry unit
    0959TRemoval or replacement of magnet from coil assembly connected to continuous bilateral electroencephalography monitoring system
    0960TReplacement of sub-scalp implanted electrode array, receiver, and telemetry unit
    0961TShortwave infrared radiation imaging of surgical pathology specimen to assist gross examination for lymph node localization
    0962TAssistive algorithmic analysis of acoustic and electrocardiogram recording for detection of cardiac dysfunction
    0963TAnoscopy with directed submucosal injection of bulking agent into anal canal
    0964TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea; single arch
    0965TDual arch jaw expansion oral prosthesis with additional mandibular advancement, non-fixed hinge mechanism
    0966TDual arch jaw expansion oral prosthesis with additional mandibular advancement, fixed hinge mechanism
    1–10 of 23
    1/3
    Emerging technology and monitoring codesCPTExperimental
    0991TCystourethroscopy with low-energy lithotripsy and acoustically actuated microspheres, including imaging
    0994TEndovascular delivery of aortic wall stabilization drug therapy through a sheath positioned within an abdominal aortic aneurysm
    0995TEndovascular delivery of aortic wall stabilization drug therapy through a sheath positioned within an abdominal aortic aneurysm
    0999TEndovascular delivery of aortic wall stabilization drug therapy; open, with guidance and radiological supervision and interpretation
    1019TLymphovenous bypass, including robotic assistance, per extremity
    1030TCreation of digital 3D model from surface mesh files of patient-specific anatomy; initial 30 minutes
    1031TCreation of digital 3D model from surface mesh files of patient-specific anatomy; each additional 30 minutes
    1032TCreation of digital 3D model and digital simulation; initial 60 minutes
    1033TCreation of digital 3D model and digital simulation; each additional 30 minutes
    1034TCreation of digital 3D model, digital simulation, and computational analyses; initial 90 minutes
    1–10 of 28
    1/3
    Category I procedures and non-covered Barostim-related codesCPTNot Covered
    53452Unilateral insertion of periurethral transperineal adjustable balloon continence device, including cystourethroscopy and imaging guidance
    53453Removal of periurethral adjustable balloon, each balloon
    53454Percutaneous adjustment of balloon(s) fluid volume
    55877Ablation, irreversible electroporation, prostate, one or more tumors, including imaging guidance
    55881Ablation of prostate tissue, transurethral, using thermal ultrasound with MRI guidance and monitoring of tissue ablation
    55882Ablation of prostate tissue, transurethral, using thermal ultrasound with MRI guidance and monitoring, including transurethral ultrasound transducer
    64567Percutaneous electrical nerve field stimulation, cranial nerves, without implantation
    64625Radiofrequency ablation of nerves innervating the sacroiliac joint, with image guidance
    64654Initial open implantation of baroreflex activation therapy modulation system
    64655Supplemental non-covered code associated with Barostim Neo System
    1–10 of 14
    1/2
    CPT and HCPCS experimental/emerging services and technologiesmixedExperimental
    55877Ablation, irreversible electroporation, prostate, 1 or more tumors, including imaging guidance, percutaneous
    55881Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; TULSA
    55882Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer
    64567Percutaneous electrical nerve field stimulation, cranial nerves, without implantation
    64625Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance
    64654Initial open implantation of baroreflex activation therapy modulation system
    64655Revision or replacement of baroreflex activation therapy modulation system, lead only
    64656Revision or replacement of baroreflex activation therapy modulation system, pulse generator only
    64657Removal of baroreflex activation therapy modulation system, total system
    64658Removal of baroreflex activation therapy modulation system, lead only
    1–10 of 29
    1/3
    HCPCS C-codesHCPCSExperimental
    C1824Generator, cardiac contractility modulation, implantable
    C1839Iris prosthesis
    C1982Catheter, pressure generating, one-way valve, intermittently occlusive
    C8003Catheter, pressure generating, one-way valve, intermittently occlusive
    C9758Blinded procedure for NYHA class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization and imaging, in an approved IDE study
    C9760Transcatheter intraoperative blood vessel microinfusion therapy
    C9764Non-randomized, non-blinded procedure for NYHA class II, III, or IV heart failure; transcatheter implantation of interatrial shunt or placebo control in an approved IDE study
    C9765Revascularization with intravascular lithotripsy, including angioplasty within the same vessel when performed
    C9772Revascularization with intravascular lithotripsy, transluminal stent placement, and/or atherectomy
    C9797Repair of enterocutaneous fistula of small intestine or colon with plug
    1–10 of 13
    1/2
    HCPCS E-codesHCPCSExperimental
    E0201Penile contracture device, manual, greater than 3 lbs. traction force
    E0231Non-contact wound warming device
    E0469Warming card for non-contact wound warming device
    E0490Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle
    E0491Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, 90-day supply
    E0675Pneumatic compression device, high pressure, rapid inflation/deflation cycle, for arterial peripheral artery disease
    E0677Non-pneumatic sequential compression garment, trunk
    E0732Cranial electrotherapy stimulation system
    E0733Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
    E0738Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education
    1–10 of 22
    1/3
    HCPCS G-, K-, L-, M-, and S-codesHCPCSExperimental
    G9894Androgen deprivation therapy prescribed or administered in combination with external beam radiotherapy to the prostate
    K1004Low frequency ultrasonic diathermy treatment device for home use, including components and accessories
    K1030External recharging system for battery for implanted cardiac contractility modulation generator, replacement only
    K1036Supplies and accessories for low frequency ultrasonic diathermy treatment device, per month
    L5991Addition to lower extremity prosthesis, osseointegrated external prosthetic connector
    L8701Powered upper extremity range of motion assist device, elbow, wrist, and hand
    L8702Powered upper extremity range of motion assist device, elbow, wrist, hand, and finger
    L8720External lower extremity sensory prosthetic device, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg
    L8721Receptor sole for use with L8720, replacement, each
    M0076Prolotherapy, joint sclerotherapy and reconstructive ligament therapy
    1–10 of 16
    1/2
    NOPAIN Act site-of-service exceptionsHCPCSCovered
    C9806The ON-Q elastomeric infusion pump may be covered for qualifying Medicare members when used for post-surgical pain management in hospital outpatient departments and ambulatory surgical centers.
    C9809The AmbIT pump may be covered for qualifying Medicare members when used for post-surgical pain management in hospital outpatient departments and ambulatory surgical centers.
    Medicare NOPAIN Act exceptionHCPCSCovered
    C9809The iovera cryoneurolysis needle may be covered for Medicare members beginning January 1, 2025, under the NOPAIN Act in hospital outpatient departments and ambulatory surgical centers.
    Medicare coverage exceptionHCPCSCovered
    E3200InTandem may be covered for Medicare members with chronic stroke walking impairments.
    West Virginia Medicaid exceptionHCPCSCovered
    S3902Ballistocardiogram may be covered under West Virginia Medicaid.
    Historical code additions and removalsmixed
    0219THistorical code reference; full description not provided
    0220THistorical code reference; full description not provided
    0222THistorical code reference; full description not provided
    0421THistorical code reference; full description not provided
    0440THistorical code reference; full description not provided
    0441THistorical code reference; full description not provided
    0442THistorical code reference; full description not provided
    0497THistorical code reference; full description not provided
    0498THistorical code reference; full description not provided
    0508THistorical code reference; full description not provided
    1–10 of 48
    1/5
    Historical code additions, removals, and coverage-specific exclusionsmixed
    C9786Historical code reference; full description not provided
    C9787Historical code reference; full description not provided
    0014MHistorical code reference; full description not provided
    0111THistorical code reference; full description not provided
    0126THistorical code reference; full description not provided
    0396THistorical code reference; full description not provided
    0405THistorical code reference; full description not provided
    0424T-0436THistorical code range; individual descriptions not provided
    0470THistorical code reference; full description not provided
    0471THistorical code reference; full description not provided
    1–10 of 40
    1/4
    Historical code additions and removalsmixed
    0408T-0411TCardiac contractility modulation code range; historical description provided only at service level
    0915T-0931TNew 2025 code range; individual descriptions not provided
    0948T-0987TNew July 2025 code range; individual descriptions not provided
    K1030Cardiac contractility modulation/Optimizer system code; full description not provided
    0668T-0670THistorical code range; individual descriptions not provided
    0672THistorical code reference; full description not provided
    0697T-0698THistorical code range; individual descriptions not provided
    0710T-0713THistorical code range; individual descriptions not provided
    0815THistorical code reference; full description not provided
    0817THistorical code reference; full description not provided
    1–10 of 21
    1/3
    Historical code additions and removalsmixed
    A6000Historical code reference; full description not provided
    A9292Historical code reference; full description not provided
    C8003-C8004Historical code range; individual descriptions not provided
    C9772-C9775Historical code range; individual descriptions not provided
    E3200Historical code reference; full description not provided
    E0738-E0739Historical code range; individual descriptions not provided
    M0076Historical code reference; full description not provided
    0414T-0418THistorical code range; individual descriptions not provided
    0443THistorical code reference; full description not provided
    0656T-0657THistorical code range; individual descriptions not provided
    1–10 of 51
    1/6
    Latest historical code additions, removals, and coverage notesmixed
    0505THistorical code reference; full description not provided
    0719THistorical code reference; full description not provided
    1027T-1053THistorical code range; individual descriptions not provided
    31660-31661Historical code range; individual descriptions not provided
    51721Historical code reference; full description not provided
    55877Historical code reference; full description not provided
    55881-55882Historical code range; individual descriptions not provided
    64567Historical code reference; full description not provided
    64654-64659Historical code range; individual descriptions not provided
    81195Historical code reference; full description not provided
    1–10 of 32
    1/4
    COMS One wound treatment area
    Applicable serviceCOMS One Therapy System concurrent optical and magnetic stimulation therapy for wound assessment and dressing care
    Initial applicationTotal wound(s) surface area less than or equal to 50 sq cm
    Additional applicationEach additional application also applies to a total wound(s) surface area less than or equal to 50 sq cm
    Digital 3D model time increments
    Digital 3D modelInitial 30 minutes; each additional 30 minutes
    Digital model with simulationInitial 60 minutes; each additional 30 minutes
    Digital model, simulation, and computational analysesInitial 90 minutes; each additional 30 minutes
    Autologous heterogeneous skin-construct graft area
    Application sitesTrunk, arms, or legs; or specified face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits
    Initial graft areaFirst 50 sq cm or less
    Additional graft areaEach additional 50 sq cm, or part thereof

    Provider Documentation and Billing Actions

    Prior Authorization

    Precertification Required for HIFU

    Obtain precertification before providing high-intensity focused ultrasound (HIFU) for benign prostate tissue ablation. This requirement applies to CPT 55880.

    • CPT 55880 requires precertification.
    Documentation Required

    Document Evidence Supporting Coverage Review

    Before submitting a service for coverage review, document the applicable evidence and review factors. Services may be considered experimental or investigational when they lack FDA approval for the relevant indication or when available evidence does not establish safety, effectiveness, improved outcomes, applicability outside research, or adequate study.

    • FDA approval for the specific relevant indication
    • Current scientific evidence and health-outcome data
    • Comparative safety and effectiveness versus alternatives
    • Evidence supporting use outside the research setting and adequate study
    Documentation Required

    Document Clinical-Trial or IDE Status

    Identify whether the service is provided in a clinical trial, Medicare-approved Investigational Device Exemption (IDE) study, or Coverage with Evidence Development (CED) study, and document the coverage requirements applicable to the member’s line of business.

    • Verify the study is Medicare-approved when applicable.
    • Apply the clinical-trial coverage position for the member’s line of business.
    • Use the CMS approved IDE studies resource when applicable.
    Documentation Required

    IDE Study Documentation Required

    For transcatheter interatrial shunt or placebo procedures, document that the service is performed in an approved IDE study and submit the applicable study and procedure documentation.

    • C9759: blinded procedure for NYHA class III/IV heart failure in an approved IDE study
    • C9764: non-randomized, non-blinded procedure for NYHA class II, III, or IV heart failure in an approved IDE study
    • Include applicable catheterization, imaging, and study-status documentation.
    Documentation Required

    Document NOPAIN Act Eligibility

    When billing qualifying non-opioid devices under the NOPAIN Act, document that the device and setting meet Medicare eligibility requirements and that it was used for postoperative pain management.

    • Qualifying Medicare non-opioid device under section 4135 of the Consolidated Appropriations Act, 2023
    • Post-surgical pain-management use
    • Eligible hospital outpatient department (HOPD) or ambulatory surgical center (ASC) setting
    • For C9809, coverage may apply for Medicare members as of January 1, 2025, in eligible HOPD or ASC settings
    Documentation Required

    Document Medical Necessity

    Ensure the medical record contains documentation supporting the applicable medical-necessity criteria. Records are subject to post-payment audit by the Health Plan at any time under the provider agreement.

    • Maintain complete medical records supporting billed services and medical necessity.
    • Be prepared for post-payment audit.

    Unsupported block type: denial_risk

    Denial Risk

    Category III/T Code Risk

    Do not assume that a Category III or other “T” code is covered or medically necessary. Unless specifically addressed by another policy, these codes are potentially experimental, investigational, and/or unproven.

    • Category III codes are temporary tracking codes for emerging technology, services, and procedures.
    • Lack of a Category III/T code in this policy does not establish coverage.
    • Review applicable NCDs, LCDs, and WV BMS guidance when coverage criteria conflict.
    Denial Risk

    Cardiac Contractility Modulation

    Do not bill or represent cardiac contractility modulation therapy as covered solely because a code is available. The Health Plan considers Optimizer systems, including the OPTIMIZER Integra CCM-D System, experimental, investigational, or unproven for all indications.

    • Affected codes include 0408T–0418T, 0915T–0931T, C1824, and K1030.
    • Related removal services may be covered for fully funded plans only for unrelated issues such as pain or infection, when otherwise eligible.
    Denial Risk

    Noncontact Near-Infrared Spectroscopy

    Do not submit noncontact near-infrared spectroscopy as medically reasonable or necessary when used for purposes other than peripheral arterial disease screening.

    • CPT 0640T is not medically reasonable or necessary under Medicare and section 1862(a)(1)(A) for other uses.
    Denial Risk

    Barostim Neo System Is Not Covered

    Do not bill the Barostim Neo System as covered. Because the system is not covered, related revisions, replacements, supplies, accessories, and supplemental services are also not covered.

    • Supplemental non-covered codes: 64655, 64656, 64657, 64658, and 64659.
    Billing Rule

    Category I Code-List Omission Does Not Establish Coverage

    Do not infer coverage from the omission of a Category I code from the policy’s code list. Omission does not establish that a service or technology is covered or medically necessary.

    • The listed Category I codes are not an all-inclusive coverage list.
    • Evaluate the service under the full policy and applicable benefit and utilization requirements.
    Billing Rule

    Policy Code-List Omission Does Not Establish Coverage

    Do not infer coverage from omission of a code from this policy’s code list. A code’s absence does not necessarily mean the related service or technology is covered.

    • Review medical necessity, benefit coverage, and applicable Medicare or Medicaid guidance independently.
    Denial Risk

    Barostim Neo-Related Services Are Not Covered

    When the Barostim Neo System is non-covered, services directly related to that system remain non-covered, including revisions, replacements, removals, supplies, accessories, and supplemental codes.

    • Apply the non-covered status to system-related services and components.
    • Supplemental codes 64655–64659 remain non-covered.
    Denial Risk

    Unestablished Prosthetic Systems

    Treat osseointegrated external prosthetic connector systems and lower-extremity sensory prosthetic systems as experimental and investigational when the policy states that established Medicare coverage criteria or guidance are unavailable.

    • L5991: osseointegrated external prosthetic connector systems, including OPRA or AXOR II systems
    • L8720 and L8721: lower-extremity sensory prosthesis systems, including Walkasins
    Denial Risk

    Exercise-Equipment Exclusion

    Do not assume coverage for Myomo MyoPro myoelectric limb orthoses. The FDA considers these devices exercise equipment, which most plans exclude.

    • Affected codes include L8701 and L8702.
    Billing Rule

    Use Correct Compression-Device Coding

    Use the compression-device code that matches the clinical indication. HCPCS E0675 is specific to peripheral artery disease and is not applicable to compression devices used to prevent venous thromboembolism.

    • For lymphedema or thromboembolism, use the applicable product codes, including E0650–E0652 or E0677 when appropriate.
    • Do not use E0675 for general venous-thromboembolism prevention compression devices.
    Denial Risk

    Failure to Meet Plan and Utilization Requirements

    Payment is not guaranteed by this policy. Claims remain subject to member benefits and eligibility, medical necessity, policy and procedure requirements, claims-editing logic, provider contracts, and applicable authorization, referral, notification, and utilization-management requirements.

    • Verify eligibility and benefits on the date of service.
    • Satisfy applicable precertification, authorization, referral, notification, and utilization requirements.
    • Apply controlling state or federal law, mandates, contract terms, and applicable coverage determinations.

    Policy Background

    This policy addresses emerging technologies and services for which clinical effectiveness, safety, or applicability to the condition being treated has not been established. Experimental or investigational status is determined through clinical-evidence review together with applicable regulatory, research, and Medicare criteria. Services meeting that status are generally non-covered, although different rules may apply when a service is furnished under an applicable clinical trial or Medicare-approved IDE/CED study.

    Key Definitions

    Experimental/investigational service
    Covered service determinationA treatment, procedure, facility, equipment, drug, service, supply, or intervention that has not been determined to be medically effective for the condition being treated
    Relevant conditionEffectiveness is evaluated for the condition being treated
    Policy consequenceServices considered experimental/investigational by this policy are deemed non-covered services
    Category III CPT code
    Code typeTemporary CPT codes for emerging technology, services, and procedures
    PurposeIntended to track usage of these services
    Data useCollected data may be used to substantiate widespread usage in the Food and Drug Administration approval process
    IDE/CED study
    Study typeA Medicare-approved study
    Study pathwaysInvestigational device exemption or coverage with evidence development
    Coverage basisCoverage follows the clinical-trial rules applicable to the member's line of business
    Histotripsy
    ProcedureHistotripsy of malignant renal tissue, including imaging guidance
    Ablation typeNon-thermal ablation
    Energy deliveryAcoustic energy delivery
    Noninvasive prostate cancer estimation map
    Map typeNoninvasive prostate cancer estimation map
    Source analysisDerived from augmentative analysis of image-guided fusion biopsy and pathology
    Reported findingsIncludes visualization of margin volume and location, margin determination, and physician interpretation and report
    COMS One Therapy System
    Therapy typeConcurrent optical and magnetic stimulation therapy
    Clinical useWound assessment and dressing care
    Clinical statusCurrently under clinical investigation and being studied in the MAVERICKS clinical trial for refractory diabetic foot ulcers
    Research unavailable
    MeaningResearch is unavailable when the treatment, procedure, equipment, drug, service, supply, or intervention has not been adequately studied
    Evidence statusThe intervention lacks adequate study
    Policy contextThe policy identifies unavailable research as a basis for experimental or investigational status